Hemodialysis Induces p66 shc Gene Expression in Nondiabetic Humans: Correlations with Oxidative Stress and Systemic Inflammation

Journal of Renal Nutrition

Volumn 21, Issue 5, 2011, Pages 401-409

  Zanetti, Michela ^a   Barazzoni, Rocco ^a   Gortan Cappellari, Gianluca ^a   Burekovic, Ismet ^a   Bosutti, Alessandra ^a   Stocca, Alessia ^a   Bianco, Francesco ^a   Ianche, Marco ^a   Panzetta, Giovanni ^a   Guarnieri, Gianfranco ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; MESSENGER RNA; PENTRAXIN 3; PROTEIN SHC; SERUM AMYLOID P; SHC1 PROTEIN, HUMAN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; INFLAMMATION; LEUKOCYTE; MALE; MIDDLE AGED; OUTPATIENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; GENE EXPRESSION; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; LEUKOCYTES; MALE; MIDDLE AGED; OUTPATIENTS; OXIDATIVE STRESS; RENAL DIALYSIS; RNA, MESSENGER; SERUM AMYLOID P-COMPONENT; SHC SIGNALING ADAPTOR PROTEINS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052070572     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2010.12.006     Document Type: Article

References (36)

1. Pupim L.B., Himmelfarb J., McMonagle E., et al. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 2004, 65:2371-2379.
2. Rysz J., Banach M., Cialkowska-Rysz A., et al. Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis. Cell Mol Immunol 2006, 3:151-154.
3. Boehme M., Kaehne F., Kuehne A., et al. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Nephrol Dial Transplant 2007, 22:2224-2229.
4. Kendrick J., Chonchol M.B. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 2008, 4:672-681.
5. Janssen-Heininger Y.M., Macara I., Mossman B.T. Cooperativity between oxidants and tumor necrosis factor in the activation of nuclear factor (NF)-kappaB: requirement of Ras/mitogen-activated protein kinases in the activation of NF-kappaB by oxidants. Am J Respir Cell Mol Biol 1999, 20:942-952.
6. Elks C.M., Mariappan N., Haque M., et al. Chronic NF-κB blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR. Am J Physiol Renal Physiol 2009, 296:F298-F305.
7. Anilkumar N., Weber R., Zhang M., et al. Nox 4 and nox 2 NADPH oxidases mediate distinct cellular redox signaling responses to agonist stimulation. Arterioscler Thromb Vasc Biol 2008, 28:1347-1354.
8. Migliaccio E., Giorgio M., Mele S., et al. The p66shc adaptor protein controls oxidative stress response and lifespan in mammals. Nature 1999, 402:309-313.
9. Nemoto S., Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 2002, 295:2450-2452.
10. Giorgio M., Migliaccio E., Orsini F., et al. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 2005, 22:221-233.
11. Khanday F.A., Santhanam L., Kasuno K., et al. Sos-mediated activation of rac1 by p66shc. J Cell Biol 2006, 172:817-822.
12. Menini S., Iacobini C., Ricci C., et al. Ablation of the gene encoding p66Shc protects mice against AGE-induced glomerulopathy by preventing oxidant-dependent tissue injury and further AGE accumulation. Diabetologia 2007, 50:1997-2007.
13. Napoli C., Martin-Padura I., de Nigris F., et al. Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet. Proc Natl Acad Sci USA 2003, 100:2112-2116.
14. Zaccagnini G., Martelli F., Fasanaro P., et al. p66shc A modulates tissue response to hindlimb ischemia. Circulation 2004, 109:2917-2923.
15. Camici G.G., Schiavoni M., Francia P., et al. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci USA 2007, 104:5217-5222.
16. Graiani G., Lagrasta C., Migliaccio E., et al. Genetic deletion of the p66Shc adaptor protein protects from angiotensin II-induced myocardial damage. Hypertension 2005, 46:433-440.
17. Francia P., delli Gatti C., Bachschmid M., et al. Deletion of p66shc gene protects against age-related endothelial dysfunction. Circulation 2004 2004, 110:2889-2895.
18. Bosutti A., Grassi G., Zanetti M., et al. Relation between the plasma levels of LDL-cholesterol and the expression of the early marker on inflammation long pentraxin 3 PTX3 and the stress response gene p66(shcA) in pacemaker-implanted patients. Clin Exp Med 2007, 7:16-23.
19. Pagnin E., Fadini G., de Toni R., et al. Diabetes induced p66shc gene expression in human peripheral blood mononucler cells: relationship to oxidative stress. J Clin Endocrinol Metab 2005, 90:1130-1136.
20. Pandolfi S., Bonafe M., Di Tella L., et al. p66(shc) is highly expressed in fibroblasts from centenarians. Mech Ageing Dev 2005, 126:839-844.
21. Valentini J., Grotto D., Paniz C., et al. The influence of the hemodialysis treatment time under oxidative stress biomarkers in chronic renal failure patients. Biomed Pharmacother 2008, 62:378-382.
22. IUPAC Compendium of Chemical Terminology 1997, Blackwell Scientific Publications, Oxford, England. 2nd ed. A.D. McNaught, A. Wilkinson (Eds.).
23. Dursun B., Dursun E., Suleymanlar G., et al. Carotid artery intima-media thickness correlates with oxidative stress in chronic haemodialysis patients with accelerated atherosclerosis. Nephrol Dial Transplant 2008, 23:1697-1703.
24. Ventura A., Luzi L., Pacini S., et al. The p66shc longevity gene is silenced through epigenetic modifications of an alternative promoter. J Biol Chem 2002, 277:22370-22376.
25. Geisel J., Schorr H., Heine G.H., et al. Decreased p66shc promoter methylation in patients with end-stage renal disease. Clin Chem Lab Med 2007, 45:1764-1770.
26. Okamura D.M., Himmelfarb J. Tipping the redox balance of oxidative stress in fibrogenic pathways in chronic kidney disease. Pediatr Nephrol 2009, 24:2309-2319.
27. Samouilidou E., Grapsa E. Effect of dialysis on plasma total antioxidant capacity and lipid peroxidation products in patients with end-stage renal failure. Blood Purif 2003, 21:209-212.
28. Wiswedel I. F(2)-isoprostanes: sensitive biomarkers of oxidative stress in vitro and in vivo: a gas chromatography-mass spectrometric approach. Methods Mol Biol 2009, 580:3-16.
29. Yang C.P., Horwitz S.B. Distinct mechanisms of taxol-induced serine phosphorylation of the 66-kDa Shc isoform in A549 and RAW 264.7 cells. Biochim Biophys Acta 2002, 1590:76-83.
30. Khanday F.A., Yamamori T., Mattagajasingh I., et al. Rac1 leads to phosphorylation-dependent increase in stability of the p66shc adaptor protein: role in Rac1-induced oxidative stress. Mol Biol Cell 2006, 17:122-129.
31. Williams L.M., Lali F., Willetts K., et al. Rac mediates TNF-induced cytokine production via modulation of NF-kappaB. Mol Immunol 2008, 45:2446-2454.
32. Suliman M.E., Qureshi A.R., Carrero J.J., et al. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. QJM 2008, 101:397-405.
33. Malaponte G., Libra M., Bevilacqua Y., et al. Inflammatory status in patients with chronic renal failure: the role of PTX3 and pro-inflammatory cytokines. Int J Mol Med 2007, 20:471-481.
34. Tarakçio[breve]glu M., Erba[breve]gci A.B., Usalan C., et al. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines. Mediators Inflamm 2003, 12:15-19.
35. Caimi G., Carollo C., Montana M., et al. Nitric oxide metabolites, leukocyte activation markers and oxidative status in dialyzed subjects. Blood Purif 2009, 27:194-198.
36. Handelman G.J., Walter M.F., Adhikarla R., et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001, 59:1960-1966.